Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

by Cortes, J., Lipton, J.H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A.-C., Craig, A.R., Michallet, M., Nicolini, F.E., Kantarjian, H.
Published 2016

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

by Jabbour, E., Kantarjian, H.M., Saglio, G., Steegmann, J.L., Shah, N.P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., Baccarani, M., Kim, D.-W., Bradley-Garelik, M.B., Mohamed, H., Wildgust, M., Hochhaus, A.
Published 2016

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

by Rassidakis, G.Z, Herold, N, Myrberg, I.H, Tsesmetzis, N, Rudd, S.G, Henter, J.-I, Schaller, T, Ng, S.-B, Chng, W.J, Yan, B, Ng, C.H, Ravandi, F, Andreeff, M, Kantarjian, H.M, Medeiros, L.J, Xagoraris, I, Khoury, J.D
Published 2020

Pronounced hypoxia in models of murine and human leukemia: High efficacy of hypoxia-activated prodrug PR-104

by Benito J., Shi Y., Szymanska B., Carol H., Boehm I., Lu H., Konoplev S., Fang W., Zweidler-McKay P.A., Campana D., Borthakur G., Bueso-Ramos C., Shpall E., Thomas D.A., Jordan C.T., Kantarjian H., Wilson W.R., Lock R., Andreeff M., Konopleva M.
Published 2018

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

by Cortes, J.E., Kim, D.-W., Pinilla-Ibarz, J., Le Coutre, P., Paquette, R., Chuah, C., Nicolini, F.E., Apperley, J.F., Khoury, H.J., Talpaz, M., DiPersio, J., DeAngelo, D.J., Abruzzese, E., Rea, D., Baccarani, M., Müller, M.C., Gambacorti-Passerini, C., Wong, S., Lustgarten, S., Rivera, V.M., Clackson, T., Turner, C.D., Haluska, F.G., Guilhot, F., Deininger, M.W., Hochhaus, A., Hughes, T., Goldman, J.M., Shah, N.P., Kantarjian, H.
Published 2016